February 20-22, 2025  •  Hilton Midtown  •  New York, NY

Session Details

CME: Current & Emerging Advanced Therapeutics in the IBD Landscape

Feb 16 2024

1:30 PM - 2:30 PM EDT

Grand Ballroom West

Whereas steroids & surgery were the main avenues of therapy for Crohn’s & Ulcerative colitis patients in the past, novel research breakthroughs have permitted a new era of advanced immunotherapies, both biologics and small molecules, to emerge that are transforming patient care and outcomes in Inflammatory Bowel Disease (IBD). Learn the latest insights into how these new agents mechanistically accomplish and target gut disease. Emerging innovations in hyperbaric oxygen therapy and mesenchymal stem cell therapy will be reviewed.

Learning Objectives:

  1. Examine the epidemiology of Inflammatory Bowel Disease (IBD).
  2. Point out key differences in the clinical presentation of the two major IBD phenotypes: Crohn’s disease and Ulcerative colitis.
  3. Identify the basic mechanisms of action of different biologic and small molecule therapies in treating IBD.
  4. Investigate new research into the role of hyperbaric oxygen, mesenchymal stem cell therapy and microbiota restorative therapy for different forms of IBD.


Penn Presbyterian Medical Center at the University of Pennsylvania

- Associate Professor of Clinical Medicine

© Diversified Communications. All rights reserved.